Should we be screening for amblyopia?

Article

Amblyopia nearly doubles the lifetime risk of bilateral visual impairment.

Amblyopia nearly doubles the lifetime risk of bilateral visual impairment (BVI), according to a study published in the November issue of the British Journal of Ophthalmology.

Redmer van Leeuwen and colleagues from the Erasmus Medical Center, Rotterdam, The Netherlands conducted a study to determine whether the excess risk of BVI among subjects with amblyopia makes it worthwhile screening these subjects.

Risk was estimated by determining the incidence of BVI in the Rotterdam Study, a population-based cohort of subjects aged 55 years or over (n=5,220), including 192 individuals with amblyopia (3.7%). A multi-state life table was used to determine risk and excess periods spent with BVI.

It was found that, the relative risk of BVI for amblyopes was 2.6 (95% confidence interval 1.4-4.5). For subjects with amblyopia, the lifetime risk of BVI was 18% and they lived with this condition for an average of 7.2 years. For non-amblyopic individuals, these figures were 10% and 6.7 years, respectively.

Amblyopia nearly doubles the lifetime risk of BVI. The authors of this study therefore believe that the results can provide data for future cost-effectiveness analyses.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.